[{"address1": "6310 Town Square", "address2": "Suite 400", "city": "Alpharetta", "state": "GA", "zip": "30005", "country": "United States", "phone": "678 990 5740", "fax": "678 990 5744", "website": "https://alimerasciences.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.", "fullTimeEmployees": 154, "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard S. Eiswirth Jr.", "age": 55, "title": "CEO & Director", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 597869, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David R. Holland", "age": 59, "title": "Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 413500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip  Ashman Ph.D.", "age": 58, "title": "President of International Operations", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 389858, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Todd Michael Wood", "age": 53, "title": "President of U.S. Operations", "yearBorn": 1970, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Elliot  Maltz CPA", "age": 38, "title": "CFO & Treasurer", "yearBorn": 1985, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason  Werner", "title": "Chief Operating Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Christopher S. Visick", "title": "VP, General Counsel & Secretary", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Dyer M.D.", "title": "Chief Retina Specialist", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.89, "open": 3.77, "dayLow": 3.77, "dayHigh": 4.05, "regularMarketPreviousClose": 3.89, "regularMarketOpen": 3.77, "regularMarketDayLow": 3.77, "regularMarketDayHigh": 4.05, "beta": 1.164, "forwardPE": -80.4, "volume": 67710, "regularMarketVolume": 67710, "averageVolume": 80871, "averageVolume10days": 104180, "averageDailyVolume10Day": 104180, "bid": 3.93, "ask": 4.87, "bidSize": 100, "askSize": 100, "marketCap": 210465088, "fiftyTwoWeekLow": 1.32, "fiftyTwoWeekHigh": 4.38, "priceToSalesTrailing12Months": 2.6062498, "fiftyDayAverage": 3.7766, "twoHundredDayAverage": 3.416975, "currency": "USD", "enterpriseValue": 265805888, "profitMargins": -0.2493, "floatShares": 8050544, "sharesOutstanding": 52354400, "sharesShort": 118605, "sharesShortPriorMonth": 304852, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0023, "heldPercentInsiders": 0.087740004, "heldPercentInstitutions": 0.9196, "shortRatio": 1.56, "shortPercentOfFloat": 0.0023999999, "impliedSharesOutstanding": 52354500, "bookValue": 0.882, "priceToBook": 4.557823, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -21391000, "trailingEps": -0.84, "forwardEps": -0.05, "lastSplitFactor": "1:15", "lastSplitDate": 1573776000, "enterpriseToRevenue": 3.292, "enterpriseToEbitda": 39.003, "52WeekChange": 1.9755735, "SandP52WeekChange": 0.31995547, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ALIM", "underlyingSymbol": "ALIM", "shortName": "Alimera Sciences, Inc.", "longName": "Alimera Sciences, Inc.", "firstTradeDateEpochUtc": 1572877800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "43b46644-06cf-3ac0-9514-3b668c1cfa9e", "messageBoardId": "finmb_10347835", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.02, "targetHighPrice": 8.0, "targetLowPrice": 6.0, "targetMeanPrice": 7.33, "targetMedianPrice": 8.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 12058000, "totalCashPerShare": 0.23, "ebitda": 6815000, "totalDebt": 67399000, "quickRatio": 2.127, "currentRatio": 2.392, "totalRevenue": 80754000, "debtToEquity": 145.98, "revenuePerShare": 3.159, "returnOnAssets": -0.012309999, "returnOnEquity": -1.5875701, "freeCashflow": -80359128, "operatingCashflow": -14261000, "revenueGrowth": 0.875, "grossMargins": 0.8658, "ebitdaMargins": 0.08439, "operatingMargins": 0.027520001, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-22"}]